Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma

Pathology Research and Practice

Volumn 205, Issue 1, 2009, Pages 11-20

  Passam, Freda H ^a   Alexandrakis, Michael G ^b   Kafousi, Maria ^b   Fotinou, Marianthi ^a   Darivianaki, Katerina ^b   Tsirakis, George ^b   Roussou, Paraskevi A ^a   Stathopoulos, Efstathios N ^b   Siafakas, Nikolaos M ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiogenesis; HIF 1 ; Hodgkin; PDGFR ; VEGF

Indexed keywords

BLEOMYCIN; CD31 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROCARBAZINE; PROTEIN P53; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; HODGKIN DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICROVESSELS; NEOPLASM STAGING; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 57249089043     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.07.007     Document Type: Article

References (63)

1. Abele M.C., Valente G., Kerim S., Navone R., Onesti P., Chiusa L., et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 82 (1997) 281-285
2. B. Agarwal, K.N. Naresh, Re: Doussis-Anagnostopoulou et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002;197:677-683, J. Pathol. 201 (2003) 334-335.
3. Alvarez R.H., Kantarjian H.M., and Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin. Proc. 81 (2006) 1241-1257
4. Arush M., Barak A., Maurice S., and Livne E. Serum VEGF as a significant marker of treatment response in Hodgkin lymphoma. Pediatr. Hematol. Oncol. 24 (2007) 111-115
5. Board R., and Jayson G.C. Platelet-derived growth factor receptor (PDGFRΑ): a target for anticancer therapeutics. Drug Resist. Updat. 8 (2005) 75-83
6. Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 11 (2005) 7658-7663
7. Brown R.E., and Nazmi R.K. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann. Clin. Lab. Sci. 32 (2002) 339-351
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
9. Carvalho I., Milanezi F., Martins A., Reis R., and Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 7 (2005) R788-795
10. Choi K., Bae M., Jeong J., Moon H., and Kim K. Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36 (2003) 120-127
11. Citak E.C., Oguz A., Karadeniz C., and Akyurek N. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol. Res. Pract. 204 (2008) 89-96
12. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172 (1990) 1535-1545
13. Doussis-Anagnostopoulou I.A., Talks K.L., Turley H., Debnam P., Tan D.C., Mariatos G., et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J. Pathol. 197 (2002) 677-683
14. Doussis I., Pezzella F., Lane D., Gatter K., and Mason D. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am. J. Clin. Pathol. 99 (1993) 663-667
15. Ferrara N., Gerber H., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
16. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
17. Folkman J., Watson K., Ingher D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
18. Foss H., Araujo I., Demel G., Klotzbach H., Hummel M., and Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J. Pathol. 183 (1997) 44-50
19. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
20. Giles F.J., Vose J.M., Do K.A., Johnson M.M., Manshouri T., Bociek G., et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk. Res. 28 (2004) 595-604
21. Glimelius I., Edstrom A., Fischer M., Nilsson G., Sundstrom C., Molin D., et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 19 (2005) 2360-2362
22. Gruss H., Pinto A., Duyster J., Poppema S., and Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol. Today 18 (1997) 156-163
23. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's diseases. International Prognostic Factors Project on Advanced Hodgkin's Disease. N. Engl. J. Med. 339 (1998) 1506-1514
24. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 78 (1998) 1379-1384
25. Jones A.V., and Cross N.C. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol. Life Sci. 61 (2004) 2912-2923
26. Kadin M., Agnarsson B., Ellingsworth L., and Newcom S. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am. J. Pathol. 136 (1990) 1209-1214
27. Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J., et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br. J. Haematol. 130 (2005) 869-877
28. Khnykin D., Troen G., Berner J., and Delabie J. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J. Pathol. 208 (2006) 431-438
29. Kilic M., Kasperczyk H., Fulda S., and Debatin K. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26 (2007) 2027-2038
30. Korkolopoulou P., Thymara I., Kavantzas N., Vassilakopoulos T.P., Angelopoulou M.K., Kokoris S.I., et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 19 (2005) 894-900
31. Lee J., Bae S., Jeong J., Kim S., and Kim K. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp. Mol. Med. 36 (2004) 1-12
32. Lister T., Crowther D., Sutcliffe S., Glatstein E., Canellos G., Young R., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwold meeting. J. Clin. Oncol. 7 (1989) 1630-1636
33. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., and Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340 (1992) 145-146
34. Mainou-Fowler T., Angus B., Miller S., Proctor S.J., Taylor P.R., and Wood K.M. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 47 (2006) 223-230
35. Manghi M. Angiogenesis and angiogenic mediators in hematological malignancies. Br. J. Haematol. 111 (2000) 43-51
36. Milkiewicz M., Ispanovic E., Doyle J., and Haas T. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int. J. Biochem. Cell Biol. 38 (2006) 333-357
37. Moehler T.M., Neben K., Ho A.D., and Goldschmidt H. Angiogenesis in hematologic malignancies. Ann. Hematol. 80 (2001) 695-705
38. Montesinos-Rongen M., Roers A., Kuppers R., Rajewsky K., and Hansmann M. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 94 (1999) 1755-1760
39. Nicolini A., Campani D., Miccoli P., Spinelli C., Carpi A., Menicagli M., et al. Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: a case-control study. Int. J. Biol. Markers 19 (2004) 275-281
40. Ohshima K., Sugihara M., Suzumiya J., Haraoka S., Kanda M., Shimazaki K., et al. Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Pathol. Res. Pract. 195 (1999) 149-155
41. Padro T., Ruiz S., Biecker R., Burger H., Steins M., Kienast J., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95 (2000) 2637-2644
42. Passam F., Alexandrakis M., Moschandrea J., Sfiridaki A., Roussou P., and Siafakas N. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int. J. Immunopathol. Pharmacol. 19 (2006) 161-170
43. Renne C., Willenbrock K., Kuppers R., Hansmann M., and Brauninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105 (2005) 4051-4059
44. Salven P. Angiogenesis in lymphoproliferative disorders. Acta Haematol. 106 (2001) 184-189
45. Schmid T., Zhou J., and Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. Cell Mol. Med. 8 (2004) 423-431
46. Schoppmann S.F., Fenzl A., Schindl M., Bachleitner-Hofmann T., Nagy K., Gnant M., et al. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Res. Treat. 99 (2006) 135-141
47. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13 (2001) 167-171
48. Stewart M., Talks K., Leek R., Turley H., Pezzella F., Harris A., et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 40 (2002) 253-260
49. Teofili L., Di Febo A.L., Pierconti F., Maggiano N., Bendandi M., Rutella S., et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97 (2001) 1063-1069
50. Toi M., Inada K., Suzuki H., and Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat. 36 (1995) 193-204
51. Trümper L.H., Brady G., Bagg A., Gray D., Loke S.L., Griesser H., et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 81 (1993) 3097-3115
52. Tzankov A., Heiss S., Ebner S., Sterlacci W., Schaefer G., Augustin F., et al. Angiogenesis in nodal B-Cell lymphomas: a high throughput study. J. Clin. Pathol. 60 (2007) 476-482
53. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
54. Vacca A., Ribatti D., Ruco L., Giacchetta F., Nico B., Quondamatteo F., et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br. J. Cancer 79 (1999) 965-970
55. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P., et al. Quantitation of angiogenesis in the solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A (1996) 2474-2484
56. Vrekoussis T., Stathopoulos E.N., Kafousi M., Navrozoglou I., and Zoras O. Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta. Oncol. Rep. 17 (2007) 1115-1119
57. Wang J., and Taylor C.R. Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: application of tissue microarray technique. Appl. Immunohistochem. Mol. Morphol. 11 (2003) 206-213
58. Weidner N., Semple J., Welch W., and Folkman J. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324 (1991) 1-8
59. In: Jaffe E., Lee Harris N., Stein H., and Vardiman J. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon
60. Xerri L., Parc P., Bouabdallah R., Camerlo J., and Hassoun J. PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease. J. Pathol. 175 (1995) 189-194
61. Xerri L., Bouabdallah R., Camerlo J., and Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum. Pathol. 25 (1994) 449-454
62. Yokote T., Akioka T., Oka S., Nakayama S., Yamano T., Hara S., et al. Vascular endothelial growth factor and interleukin 6 expression by Hodgkin/Reed Stenberg cells. Br. J. Haematol. 125 (2004) 1
63. Zhao W.L., Mourah S., Mounier N., Leboeuf C., Daneshpouy M.E., Legrès L., et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab. Invest. 84 (2004) 1512-1519